Combo of SGLT2 Inhibitor + GLP-1 RA Boosts Diabetes Survival

Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class alone.
Medscape Medical News
Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class alone.
Medscape Medical News